AleAnna, Inc. Warrant (ANNAW) is a forward-looking biopharmaceutical entity focused on developing innovative therapies to address critical unmet medical needs. The company utilizes advanced technologies to drive its research and clinical development efforts, featuring a promising pipeline of unique drug candidates designed to enhance patient outcomes. With strategic partnerships across the healthcare sector, AleAnna is poised for successful commercialization of its pioneering therapeutics, representing a substantial growth opportunity for investors within the evolving biopharmaceutical market.
| Revenue (TTM) | $33.73M |
| Gross Profit (TTM) | $26.83M |
| EBITDA | $13.23M |
| Operating Margin | 33.00% |
| Return on Equity | 17.70% |
| Return on Assets | 6.62% |
| Revenue/Share (TTM) | $0.83 |
| Book Value | $0.90 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | -97.10% |
| Quarterly Revenue Growth (YoY) | 1349.00% |
| Shares Outstanding | 0 |
| Float | $9.57M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |